<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936013</url>
  </required_header>
  <id_info>
    <org_study_id>Z09000700090903－2</org_study_id>
    <nct_id>NCT00936013</nct_id>
  </id_info>
  <brief_title>Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study</brief_title>
  <official_title>Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Pneumonia: Multi-centre, Prospective, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether the combination treatment of Chinese
      medicinal herbs and oseltamivir is more effective than single oseltamivir in treating novel
      influenza A (H1N1) pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The antiviral agent, oseltamivir, is recommended by the World Health Organization (WHO) to
      treat recent outbreak novel influenza A (H1N1) virus infection around world. But limited
      stock and resistant strain emergence raised increasing concerns. Chinese medicinal herbs, are
      derived from plants and usually incorporate one or more herbs as the basic drug(s) to treat
      the disease. The investigators performed RCT to indicate that a combination treatment of
      Chinese medicinal herbs and oseltamivir is more effective than single oseltamivir in treating
      novel influenza A (H1N1) pneumonia.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy rate in 5 days (defined as failure: SaO2&lt;90% at room air or temperature elevated continuously)</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever(defined as the period from start of study-drug to relief of fever)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of respiratory symptoms(defined as the period from start of study-drug to relief of symptoms)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virus shedding time</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infiltration resolution of chest radiology</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SaO2 and PaO2/FiO2(arterial blood gas)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>oseltamivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single antiviral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oseltimivir and chinese medicinal herbs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oseltamivir</intervention_name>
    <description>75mg p.o Bid for 5 days</description>
    <arm_group_label>oseltamivir</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oseltamivir and chinese medicinal herbs</intervention_name>
    <description>oseltamivir: 75mg p.o bid for 5 days chinese medicinal herbs:200ml p.o qid for 5 days</description>
    <arm_group_label>oseltimivir and chinese medicinal herbs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed novel influenza A(H1N1) case with laboratory evidence

          -  70 ys ≥ age ≥14ys

          -  Within 72hr after the onset of symptoms(body temperature≥37.5℃ with at least one
             respiratory symptom (cough, sore throat, or nasal symptom)

          -  New lung infiltration showed by chest radiology(x-ray or CT)

        Exclusion Criteria:

          -  Age&lt;14ys or &gt;70ys

          -  Pregnancy

          -  Severe chronic underlying diseases: severe COPD(FEV1/EVC &lt;70% and FEV1 &lt;30% predicted
             or respiratory failure or congestive heart failure), severe liver disfunction（ALT or
             AST ≥3 times normal elevation), renal disfunction（Cr&gt;2mg/dL), chronic heart
             failure(NYHA Ⅲ-Ⅳ grade）

          -  Immunocompromised patients(cancer, organ transplant, AIDS and a history of treatment
             with immunosuppressive drug and glucocorticoids in the past 3 months)

          -  Taken Chinese medicinal herbs, antiviral or antibiotic drug in the past 2 weeks

          -  Inoculation influenza vaccination

          -  One of the following items appeared at the enrollment

               -  respiratory failure：PaO2&lt;60mmHg and/or PCO2&gt;50mmHg or PaO2/FiO2≤300

               -  circulation failure: despite adequate fluid resuscitation and cardiac output,
                  systolic &lt;90mmHg or requirement inotropic support

               -  renal function failure: despite adequate fluid resuscitation and cardiac output,
                  urine ≤ 0.5ml/kg.h, Cr or BUN≥1 time normal elevation

               -  liver function failure: total bilirubin&gt;34μmol/L or ALT/AST ≥3 times normal
                  elevation

          -  Other unappropriated enrollment situations considered by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Wang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qingquan Liu, Docter</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Chinese Traditional Medicine University affiliated Dongzhimen Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu Mao, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Ditan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bin Cao, Doctor</last_name>
    <phone>86-010-85231999</phone>
    <email>caobin1999@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Gu, Doctor</last_name>
    <phone>86-85231133</phone>
    <email>guliangel@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Capital Medical University affiliated Bejing Chaoyang Hospital, Beijing Respiratory Medicine Institute</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Cao, Doctor</last_name>
      <phone>86-010-85231167</phone>
      <email>caobin1999@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bin Cao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2009</study_first_posted>
  <last_update_submitted>November 1, 2009</last_update_submitted>
  <last_update_submitted_qc>November 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Wang Chen</name_title>
    <organization>Capital Medical University affiliated Beijing Chaoyang Hospital</organization>
  </responsible_party>
  <keyword>novel influenza A(H1N1)</keyword>
  <keyword>chinese medicinal herbs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

